How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

Direct-to-patient is more than just telehealth – with EVERSA...

Unifying observational research with a next-generation virtu...

Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.

New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an...

At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

For the continuum of mental health we need a whole system, h...

If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow.

The growing burden of misinformation: Patients left wonderin...

It’s no secret that challenges related to misinformation are rising, as more people rely on personalised news feeds and non-traditional information channels across the internet and social m